23andMe controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2026
California settles data breach claims against 23andMe
Settlement
California announced a US$6 million settlement payment in 23andMe's bankruptcy, resolving the state's legal claims related to a 2023 data breach that exposed customers' genetic and other personal information. California also agreed to drop further appeals over the asset sale as part of the settlement.
Source excerpt
California Attorney General Rob Bonta on Monday announced the state will receive a $6 million settlement payment in 23andMe's bankruptcy, resolving California's legal claims related to a 2023 data breach that exposed 6.9 million customers' genetic and other personal information.
California Attorney General Rob Bonta on Monday announced the state will receive a US$6 million settlement payment in 23andMe’s bankruptcy, resolving California’s legal claims related to a 2023 data breach that exposed 6.9 million customers’ genetic and other personal information.
California lost an appeal over the sale in federal district court, and it agreed to drop further appeals as part of the $6 million settlement, according to court documents filed on Monday.
2025
Privacy concerns during bankruptcy
The bankruptcy and proposed transfer of a large genetic database prompted consumer and regulatory concern about deletion rights, retention obligations, and the future ownership or transfer of sensitive genetic information. California’s attorney general issued a consumer alert reminding residents of their privacy rights.
2019
Celmatix sues 23andMe over research contract
Lawsuit filed
Celmatix sued 23andMe, seeking over $100 million in damages. The lawsuit alleges that 23andMe breached a research contract and caused Celmatix financial setbacks. The source gives conflicting filing days, so the publication date is used.
Source excerpt
Celmatix filed the lawsuit on Monday, where it is asking for over $100 million in damages.
At that point, Celmatix claims that 23andMe then made steps to thwart its financing round.